Research and progress in the treatment of cardiovascular diseases with metabolic drugs
10.12092/j.issn.1009-2501.2025.07.014
- VernacularTitle:代谢药物治疗心血管疾病的研究与进展
- Author:
Min SUN
1
;
Hongya WANG
1
;
Hongbo HE
1
;
Zhiming ZHU
1
;
Peng GAO
1
Author Information
1. 陆军军医大学陆军特色医学中心高血压内分泌科,重庆 400042
- Publication Type:Journal Article
- Keywords:
cardiovascular diseases;
hypoglyce-mic drugs;
PCSK9 inhibitors;
Ezetimibe
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2025;30(7):984-997
- CountryChina
- Language:Chinese
-
Abstract:
Cardiovascular disease(CVD),as one of the diseases with the highest morbidity and mor-tality rates globally,has always been a focus of med-ical research.In recent years,with a deeper under-standing of the pathogenesis of CVD,novel metabol-ic drugs have demonstrated great potential in its treatment.These novel drugs regulate multiple as-pects of cardiovascular metabolism,including reduc-ing blood glucose and lipid levels,inhibiting inflam-matory responses,and protecting vascular endothe-lial cells,thereby providing new strategies for the prevention and treatment of CVD.In terms of lower-ing blood glucose levels,SGLT2 inhibitors,GLP-1 re-ceptor agonists,DPP-4 inhibitors,and Metformin,as clinically commonly used drugs,have been prov-en to be beneficial for the prevention and treat-ment of CVD,regardless of the presence or absence of diabetes.For lipid regulation,PCSK9 inhibitors and Ezetimibe,as newly developed lipid-lowering drugs,not only reduce serum low-density lipopro-tein cholesterol levels but also directly protect the cardiovascular system from damage.The develop-ment and application of these drugs have not only improved the treatment outcomes of CVD but also provided patients with more therapeutic options.
